July 29, 2019–Exact Sciences and Genomic Health announced today that the companies have entered into a definitive agreement in which Exact Sciences will combine with Genomic Health for $2.8 billion. The two companies will create a worldwide cancer diagnostics company, joining its two brands Cologuard and Oncotype DX, respectively. The combined company expects to generate revenue of approximately $1.6 billion and gross profit of approximately $1.2 billion in 2020.
Read More »Home >> Tag Archives: Genomic Health
Genomic Health, Epic Sciences collaboration, 9/16
September 2016—Genomic Health and Epic Sciences announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the U.S. through Genomic Health’s commercial channel. The blood-based test detects the V7 variant of the androgen receptor protein in the nucleus of circulating tumor cells—information that can help guide treatment selection in patients with metastatic castration-resistant prostate cancer.
Read More »Oncotype DX prostate cancer test, 9/13
Genomic Health made its Oncotype DX prostate cancer test available recently after a presentation of a positive clinical validation study by the University of California, San Francisco, at this year’s American Urological Association annual meeting.
Read More »